Skip to main content
Premium Trial:

Request an Annual Quote

Mission Bio, SequMed Ink Collaboration, Clinical Assay Codevelopment Agreement for China

NEW YORK – Single-cell DNA sequencing firm Mission Bio said on Thursday that it has signed an agreement with China's SequMed to collaborate on services and the development of clinical applications.

Under the terms of the agreement, the firms will work together to combine Mission Bio's Tapestri platform with SequMed's clinical assay development and data analysis capabilities to create new single-cell assays for cancer early detection, therapy selection, and prognosis monitoring. They will also work on applications in reproductive genetics.

"By integrating our single-cell technology with SequMed's expertise in clinical assay development, we are committed to improving diagnosis, prognosis, and treatment of diseases in China," Yan Zhang, CEO of Mission Bio, said in a statement.

SequMed, founded in 2017, is a single-cell genomics services provider based in Guangzhou, China.

Mission Bio, based in South San Francisco, California, has previously partnered with other firms to expand its business in China. Earlier this year, it teamed up with Sequanta Technologies to offer single-cell sequencing services in mainland China, and in 2019, it signed a distribution deal for that country with Novogene.

The Scan

Close Panel Vote on Califf Nomination

The New York Times reports there was a close committee vote to advance the nomination of Robert Califf to lead the US Food and Drug Administration to the full Senate.

Task Force Reports on Scientific Integrity

Nature News writes that that a new task force report recommends that the US establish a cross-agency scientific integrity council.

Across the Hall

Genetic testing, closed-circuit cameras, and more show how a traveler, without any contact, infected others at a New Zealand quarantine facility, CNN reports.

Science Paper Examines Influence of Chromatin Modifications on Obsessive-Compulsive Disorder

In Science this week: genes regulating chromatin modification may contribute to OCD risk.